A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2018
At a glance
- Drugs Doxorubicin (Primary) ; Olaratumab (Primary)
- Indications Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Acronyms ANNOUNCE
- Sponsors Eli Lilly
- 24 Jan 2018 According to an Eli Lilly media release, results are expected in 2020.
- 25 Aug 2017 Planned End Date changed from 1 Sep 2020 to 1 Jan 2020.
- 25 Aug 2017 Planned primary completion date changed from 1 Mar 2019 to 1 Jan 2019.